PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells

Linglong Yin, Youhong Liu, Yuchong Peng, Yongbo Peng, Xiaohui Yu, Yingxue Gao, Bowen Yuan, Qianling Zhu, Tuoyu Cao, Leye He, Zhicheng Gong, Lunquan Sun, Xuegong Fan, Xiong LiJournal of Experimental & Clinical Cancer Research 2018 · DOI

Abstract

This study explores a novel therapeutic strategy for advanced prostate cancer (PCa) by combining the PARP inhibitor veliparib with the HDAC inhibitor SAHA. Our research reveals that this combination induces synergistic lethality by promoting DNA damage and inhibiting Homologous Recombination (HR) repair pathways. Specifically, the treatment targets the UHRF1/BRCA1 protein complex, destabilizing the DNA repair machinery. These findings suggest that the veliparib and SAHA combination holds significant potential for future clinical trials in metastatic castration-resistant prostate cancer (mCRPC).

Introduction

Metastatic castration-resistant prostate cancer remains a major clinical challenge, often resistant to standard therapies. While PARP inhibitors like olaparib are effective in patients with specific BRCA1/2 mutations, many patients lack these genetic markers. This study investigates whether Histone Deacetylase (HDAC) inhibitors can induce a state of "BRCAness"—effectively making cancer cells deficient in DNA repair—thereby sensitizing them to PARP inhibition regardless of their baseline genetic status.

Methodology

To validate the synergistic potential of SAHA and veliparib, a multi-disciplinary approach was employed:

  • Cell Line Profiling: A diverse panel of PCa cell lines (LNCaP, VCaP, PC-3, DU145, C4-2, CWR22Rv1) and a normal prostate epithelial line (RWPE-1) were analyzed.
  • Synergy Analysis: Crystal violet assays and Combination Index (CI) calculations were used to determine drug interactions.
  • Mechanism Mapping: Western blotting and Co-Immunoprecipitation (Co-IP) were used to study protein interactions, while immunofluorescence for $\gamma$H2AX visualized DNA damage foci.
  • In Vivo Validation: The efficacy of the combination was tested in DU145 xenograft mouse models to observe tumor growth inhibition in a physiological system.

Results

Baseline Sensitivity and Protein Expression

Initial characterization focused on the response of various prostate cell lines to SAHA treatment. As shown in Figure 6, PCa cell lines exhibited varying degrees of sensitivity to SAHA, with significant reductions in viability and colony formation observed at higher concentrations. Crucially, the normal RWPE-1 line showed greater resilience compared to most cancer lines. Baseline Western blot analysis revealed the expression levels of BRCA1 and BRCA2 across the panel, providing a reference for how drug treatments might later modulate these repair proteins.

Figure 6: Sensitivity of prostate cell lines to SAHA and baseline BRCA expression. (a) Crystal violet staining and (b) cell viability curves show the dose-dependent effect of SAHA. (c) Western blot analysis reveals baseline levels of BRCA1 and BRCA2 across the cell panel.

Synergistic Lethality and the UHRF1/BRCA1 Axis

The combination of veliparib and SAHA demonstrated potent synergistic cell killing across all tested PCa lines. For instance, in DU145 cells, the Combination Index was 0.85, indicating a clear synergistic effect. Mechanistically, the researchers discovered that SAHA treatment leads to the depletion of UHRF1, a protein that acts as a scaffold to stabilize BRCA1. The loss of UHRF1 triggers the degradation of BRCA1, effectively disabling the HR repair pathway and inducing a state of "BRCAness."

This induced deficiency leads to a massive accumulation of unrepaired double-strand DNA breaks, evidenced by a dramatic increase in $\gamma$H2AX protein levels and nuclear foci. In mouse models, this translated to significant tumor suppression without causing systemic toxicity or weight loss.

Discussion and Future Directions

This research provides a compelling mechanistic foundation for a new clinical strategy: using HDAC inhibitors to "prime" prostate cancer cells for PARP inhibition. By targeting the UHRF1/BRCA1 axis, this approach could expand the eligible patient population for PARP inhibitors beyond those with inherent BRCA mutations.

Future work must address the complexity of other DNA repair pathways that may be influenced by HDAC inhibition and refine clinical dosing ratios (currently optimized at 1:20 SAHA to veliparib in the lab) to ensure safety and efficacy in human patients. Moving toward patient-derived organoid models will be essential to account for the high degree of heterogeneity seen in clinical prostate cancer.

Summary updated

Abstract

Our studies revealed that the synergistic lethality of HDAC and PARP inhibitors resulted from promoting DNA damage and inhibiting HR DNA damage repair pathways, in particular targeting the UHRF1/BRCA1 protein complex. The synergistic lethality of veliparib and SAHA shows great potential for future PCa clinical trials.
BibTeX
@article{yin2018parp,
  author = {Linglong Yin and Youhong Liu and Yuchong Peng and Yongbo Peng and Xiaohui Yu and Yingxue Gao and Bowen Yuan and Qianling Zhu and Tuoyu Cao and Leye He and Zhicheng Gong and Lunquan Sun and Xuegong Fan and Xiong Li},
  title = {{PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells}},
  journal = {Journal of Experimental \& Clinical Cancer Research},
  year = {2018},
  doi = {10.1186/s13046-018-0810-7},
}
Figure